BiotechTube

Perampanel + Placebo

ApprovedWithdrawn
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Epilepsy, Partial

Conditions

Epilepsy, Partial

Trial Timeline

Mar 1, 2015 → Aug 1, 2016

NCT ID
NCT02220972

About Perampanel + Placebo

Perampanel + Placebo is a approved stage product being developed by Eisai for Epilepsy, Partial. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02220972. Target conditions include Epilepsy, Partial.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy, Partial were approved

Approved (20) Terminated (5) Active (0)
✅ZonegranEisaiApproved
✅perampanelEisaiApproved
✅Perampanel Oral TabletEisaiApproved
✅PerampanelEisaiApproved
✅zonisamide low dose group + zonisamide high dose groupEisaiApproved
✅Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved
✅zonisamideEisaiApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT02220972ApprovedWithdrawn
NCT01618695Phase 3Completed
NCT01161524Phase 2Completed
NCT00566462Phase 2Terminated

Competing Products

20 competing products in Epilepsy, Partial

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
35
LacosamideUCBPhase 3
40
Zonisamide + PlaceboEisaiPhase 3
32
ZonegranEisaiApproved
35
perampanel + perampanelEisaiPhase 1
29
perampanelEisaiApproved
35
E2007 + PlaceboEisaiPhase 2
35
Placebo + RufinamideEisaiPhase 3
40
E2007 (perampanel) + PlaceboEisaiPhase 2
35
Perampanel Oral TabletEisaiApproved
43
perampanelEisaiPhase 3
40
PerampanelEisaiPre-clinical
26
Zonisamide + CarbamazepineEisaiPhase 3
40
PerampanelEisaiApproved
43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
29
PerampanelEisaiPhase 2
35
Zonisamide + PlaceboEisaiPhase 3
40
zonisamide low dose group + zonisamide high dose groupEisaiApproved
43
E2007 + E2007 + PlaceboEisaiPhase 2
35
Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved
35